HINDHIGH SIGNALMANAGEMENT10-K

HIND completed a transformational merger with Vyome Therapeutics, fundamentally changing from a weight-loss medical device company to what appears to be a therapeutics-focused entity.

The merger represents a complete business pivot away from the company's historical focus on FDA-approved Lap-Band systems and obesity management solutions. This strategic transformation carries substantial execution risk as the company abandons its established market position and physician relationships to enter an entirely different therapeutic domain.

Comparing 2026-03-18 vs 2025-04-04View on EDGAR →
FINANCIAL ANALYSIS

The financial results reflect a company in significant operational distress, with gross profit collapsing to minimal levels and net losses expanding meaningfully despite reduced R&D spending. While total assets increased modestly and current liabilities declined substantially, the dramatic deterioration in fundamental profitability metrics suggests the merger may have been driven by financial necessity rather than strategic opportunity. The substantial reduction in accounts receivable and inventory indicates either severe business contraction or accounting effects from the merger transaction.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-100%
$1.0M→325

Receivables declined — improved collection efficiency or conservative revenue recognition.

Gross Profit
P&L
-95.7%
$5.1M→$219K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

R&D Expense
P&L
-67.4%
$1.8M→$588K

R&D spending cut 67.4% — could signal cost discipline or concerning reduction in innovation investment.

Total Liabilities
Balance Sheet
-45.8%
$5.0M→$2.7M

Liabilities reduced 45.8% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-45.1%
$5.0M→$2.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Net Income
P&L
-43.9%
-$7.1M→-$10.3M

Net income declined 43.9% — review whether driven by operations, interest costs, or non-recurring items.

Total Assets
Balance Sheet
+35.6%
$4.8M→$6.5M

Asset base grew 35.6% — expansion through organic growth, acquisitions, or capital deployment.

Operating Income
P&L
-35.3%
-$7.7M→-$10.5M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Total Debt
Balance Sheet
+34.2%
$9.9M→$13.3M

Debt increased 34.2% — substantial leverage increase; assess whether deployed for growth or covering losses.

Inventory
Balance Sheet
-34.2%
$3.7M→$2.5M

Inventory drawn down 34.2% — strong sell-through or deliberate destocking; watch for supply constraints.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-04-04
ADDED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
As of March 17, 2026, 7,018,528 shares of the registrant s common stock were outstanding.
F orward-looking statements and associated risks All statements in this Form 10-K that do not directly and exclusively relate to historical facts constitute forward-looking statements within the meaning of the safe harbor provisions of the U.S.
We may, in some cases, use terms such as anticipates, believes, could, estimates, expects, intends, may, plans, potential, predicts, projects, should, will, would or similar expressions that convey uncertainty of future events or outcomes to identify forward-looking statements.
BUSINESS Our Company On August 15, 2025, ReShape Lifesciences Inc.
(now known as Vyome Holdings, Inc.) (the Company ) completed the merger pursuant to the Agreement and Plan of Merger, dated as of July 8, 2024, as amended (the Merger Agreement ), by and among the Company, Raider Lifesciences Inc., a wholly owned subsidiary of the Company ( Merger Sub ), and Vyome Therapeutics, Inc.
Pursuant to the Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the Merger ).
As a result of the Merger, the Company was renamed Vyome Holdings, Inc.
and Vyome continued under its name as Vyome Therapeutics, Inc., in each case effective before the open of trading on August 15, 2025.
The Company is a Cambridge, MA/Princeton, NJ/New Delhi, India-based clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions, with a business advantage of the US-India innovation corridor.
REMOVED
(Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 18 Technology Dr.
As of April 2, 2025, 11,276,248 shares of the registrant s Common Stock were outstanding.
is a premier physician-led weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease throughout the care continuum.
Food and Drug Administration ( FDA ) approved and reimbursed Lap-Band and the recently approved Lap-Band 2.0 FLEX systems, which provide minimally invasive, long-term treatment of obesity and is a safer surgical alternative to more invasive and extreme surgical stapling procedures such as the gastric bypass or sleeve gastrectomy.
Hickey joined ReShape as President and Chief Executive Officer.
Under this new leadership, our Company has pivoted its business strategy with the intent of helping to ensure growth and profitability.
Our Company has executed the following three growth strategies, or pillars for growth: Growth Pillar I: Executing disciplined, metrics-driven business operations.
In executing the first growth pillar, our Company is focused on revenue growth and profitability.
The timeline for profitability is dependent on many factors, including revenue growth from new product introductions, or strategic investments not yet foreseen.
This first growth pillar remains, in our Company s opinion, paramount for ReShape to deliver shareholder value and, ultimately, profitability.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →